DiaMedica Therapeutics (NASDAQ:DMAC) Price Target Raised to $10.00 at HC Wainwright

DiaMedica Therapeutics (NASDAQ:DMAC) had its price objective boosted by stock analysts at HC Wainwright from $7.00 to $10.00 in a note issued to investors on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s price objective points to a potential upside of 91.94% from the company’s previous close.

DiaMedica Therapeutics Stock Performance

DiaMedica Therapeutics stock opened at $5.21 on Wednesday. The firm’s 50 day moving average price is $5.95 and its two-hundred day moving average price is $5.10. The firm has a market cap of $222.78 million, a PE ratio of -9.30 and a beta of 1.52. DiaMedica Therapeutics has a twelve month low of $2.14 and a twelve month high of $6.82.

DiaMedica Therapeutics (NASDAQ:DMAC) last announced its quarterly earnings data on Monday, March 17th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.01). Equities analysts anticipate that DiaMedica Therapeutics will post -0.59 EPS for the current fiscal year.

Institutional Trading of DiaMedica Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Point72 Asia Singapore Pte. Ltd. acquired a new position in DiaMedica Therapeutics during the third quarter worth $40,000. Balyasny Asset Management L.P. acquired a new position in DiaMedica Therapeutics during the fourth quarter worth $79,000. Y Intercept Hong Kong Ltd acquired a new stake in shares of DiaMedica Therapeutics in the fourth quarter valued at about $81,000. Raymond James Financial Inc. acquired a new stake in shares of DiaMedica Therapeutics in the fourth quarter valued at about $83,000. Finally, Bank of Montreal Can acquired a new stake in shares of DiaMedica Therapeutics in the fourth quarter valued at about $84,000. 10.12% of the stock is currently owned by hedge funds and other institutional investors.

About DiaMedica Therapeutics

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.